European CHMP recommends approval of Carmustine Obvius for use as a conditioning treatment prior to autologous haematopoietic progenitor cell transplantation

The CHMP has issued a positive opinion recommending the approval of this additional indication for Carmustine Obvius, in patients with malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma).


European Medicines Agency